Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TransMolecular, a biotechnology company, has appointed Robert Radie as its new president and CEO. The company also promoted Michael Egan, former president and CEO, to the position of vice chairman of the board.
Subscribe to our email newsletter
Prior to joining TransMolecular, Mr Radie was executive vice president and chief business officer at Prestwick Pharmaceuticals, and vice president of project management and chief business officer at Morphotek.
In addition, Mr Radie previously held the position of senior vice president of strategic projects and planning at Vicuron Pharmaceuticals. Mr Radie holds a bachelor of science degree in chemistry from Boston College.
Nicholas Nicolaides, chairman of board of directors at TransMolecular, said: “Bob’s track record of successful corporate development transactions comes at an important time in the evolution of TransMolecular. Michael’s continued involvement and counsel as vice chairman will provide a smooth transition, as he has been instrumental to TransMolecular’s success, both clinically and corporately, since joining the company.”